Journal of Food Bioactives, ISSN 2637-8752 print, 2637-8779 online |
Journal website www.isnff-jfb.com |
Original Research
Volume 3, Number , September 2018, pages 124-132
α-Glucosidase inhibitory activities, functional properties, and safety of green tea polysaccharides as a potential source of dietary supplement
Figures
Limit test procedure.
Molecular weight distribution of green tea polysaccharides.
FT-IR spectra of green tea polysaccharides.
Percentage viability of green tea polysaccharides. Data are expressed as the mean ± SD (n = 3).
The results of AMES microplate format test of green tea polysaccharides in TA 98 and TA 100 strains (— 2-fold induction over the baseline).
Tables
Criteria | Description |
---|---|
If baseline is ≤ 3 | |
2–3 times greater than baseline | weak mutagen |
>3 times greater than baseline | mutagen |
If baseline is > 3 | |
1.5–2.5 times greater than baseline | weak mutagen |
>2.5 times greater than baseline | mutagen |
Parameters | Units | GTPS |
---|---|---|
Abbreviations: ABTS, 2,2′-azino-bis (3-ethylbenzothiazoline-6-sulphonic acid); FRAP, ferric reducing antioxidant potential; GAE, gallic acid equivalents; GTPS, green tea polysaccharides; TE, trolox equivalents. Data are expressed as the mean ± SD (n = 3). | ||
Yield | % | 3.05 ± 0.15 |
Total carbohydrates | % | 34.33 ± 2.00 |
Protein | % | 2.21 ± 0.05 |
Uronic acid | % | 15.11 ± 1.55 |
Total phenolics | g GAE/100 g GTPS | 5.80 ± 0.52 |
ABTS | mg TE/100 mg GTPS | 42.51 ± 1.03 |
FRAP | mg FeSO4·7H2O /100 mg of GTPS | 19.86 ± 1.52 |
Monosaccharide composition | ||
Mannose | mol ratio % | 3.97 ± 0.00 |
Ribose | 5.95 ± 0.00 | |
Rhamnose | 3.06 ± 0.00 | |
Glucuronic | 2.02 ± 0.26 | |
Galacturonic | 0.95 ± 0.23 | |
Glucose | 16.61 ± 0.00 | |
Galactose | 40.22 ± 0.02 | |
Xylose | 1.37 ± 0.02 | |
Arabinose | 24.13 ± 0.01 | |
Fucose | 1.72 ± 0.03 |
Concentration (mg/mL) | Inhibition (%) |
---|---|
Data are expressed as the mean ± SD (n = 3). | |
2.5 | 95.25 ± 3.13 |
1.25 | 93.41 ± 3.30 |
0.5 | 91.86 ± 0.04 |
0.125 | 43.77 ± 1.73 |
0.025 | 7.15 ± 5.25 |
Concentration (mg/mL) | Positive wells | Baseline | Mutagenicity | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
TA 98 | Positive wells | Baseline | TA 100 | |||||||||
Fold increase (over the baseline) | Fold increase (over the baseline) | |||||||||||
S9+ | S9− | S9+ | S9− | S9+ | S9− | S9+ | S9− | S9+ | S9− | S9+ | S9− | |
Data are expressed as the mean ± SD (n = 3). *P < 0.05, significant level according to the student-t test. ***P < 0.001, significant level according to the student-t test. | ||||||||||||
0.156 | 2.83 ± 1.83 | 3.00 ± 1.00 | 4.67 | 4.37 | 0.50 | 0.69 | 4.33 ± 1.21 | 5.00 ± 1.00 | 5.54 | 4.59 | 0.66 | 1,09* |
0.313 | 2.33 ± 0.58 | 2.67 ± 0.58 | 0.93 | 0.61 | 3.67 ± 0.58 | 6.00 ± 1.73 | 1.02 | 1.31* | ||||
0.625 | 4.33 ± 0.58 | 3.00 ± 2.00 | 0.57 | 0.69 | 5.67 ± 0.58 | 6.33 ± 2.89 | 1.20*** | 1.38* | ||||
1.250 | 2.67 ± 1.53 | 3.00 ± 1.73 | 0.57 | 0.69 | 6.67 ± 1.53 | 4.67 ± 1.53 | 0.60 | 1.02 | ||||
2.500 | 4.67 ± 3.06 | 2.33 ± 0.58 | 1.00 | 0.53 | 3.33 ± 1.15 | 5.67 ± 2.08 | 1.14* | 1.24* | ||||
5.000 | 6.67 ± 1.53 | 5.00 ± 0.00 | 1.43*** | 1.14* | 7.33 ± 0.58 | 6.67 ± 0.58 | 1.32*** | 1.45*** |